Fayez Sarofim & Co’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $389M | Sell |
423,173
-1,223
| -0.3% | -$1.24M | 1% | 30 |
|
|
2025
Q4 | $456M | Sell |
424,396
-11,766
| -3% | -$11.3M | 1.09% | 28 |
|
|
2025
Q3 | $333M | Buy |
436,162
+10,522
| +2% | +$7.83M | 0.77% | 39 |
|
|
2025
Q2 | $332M | Sell |
425,640
-17,947
| -4% | -$13.9M | 0.8% | 39 |
|
|
2025
Q1 | $366M | Buy |
443,587
+48,290
| +12% | +$40.2M | 0.91% | 33 |
|
|
2024
Q4 | $305M | Buy |
395,297
+27,422
| +7% | +$22.7M | 0.74% | 41 |
|
|
2024
Q3 | $326M | Buy |
367,875
+36,136
| +11% | +$32.5M | 0.83% | 36 |
|
|
2024
Q2 | $300M | Buy |
331,739
+25,270
| +8% | +$20.2M | 0.81% | 38 |
|
|
2024
Q1 | $238M | Buy |
306,469
+1,072
| +0.4% | +$763K | 0.71% | 43 |
|
|
2023
Q4 | $226M | Buy |
305,397
+36,242
| +13% | +$21.2M | 0.69% | 42 |
|
|
2023
Q3 | $145M | Buy |
269,155
+35,968
| +15% | +$18.5M | 0.49% | 53 |
|
|
2023
Q2 | $109M | Buy |
233,187
+33,909
| +17% | +$14.2M | 0.38% | 57 |
|
|
2023
Q1 | $68.4M | Buy |
199,278
+54,326
| +37% | +$18.3M | 0.24% | 64 |
|
|
2022
Q4 | $53M | Buy |
144,952
+110,467
| +320% | +$39.2M | 0.2% | 66 |
|
|
2022
Q3 | $11.2M | Buy |
34,485
+425
| +1% | +$135K | 0.04% | 90 |
|
|
2022
Q2 | $11M | Buy |
34,060
+1,190
| +4% | +$357K | 0.04% | 92 |
|
|
2022
Q1 | $9.41M | Buy |
32,870
+1,148
| +4% | +$295K | 0.03% | 97 |
|
|
2021
Q4 | $8.76M | Buy |
31,722
+2,301
| +8% | +$583K | 0.03% | 104 |
|
|
2021
Q3 | $6.8M | Sell |
29,421
-156
| -0.5% | -$38.5K | 0.02% | 107 |
|
|
2021
Q2 | $6.79M | Buy |
29,577
+1,894
| +7% | +$380K | 0.02% | 106 |
|
|
2021
Q1 | $5.17M | Sell |
27,683
-4,174
| -13% | -$816K | 0.02% | 103 |
|
|
2020
Q4 | $5.38M | Sell |
31,857
-765
| -2% | -$114K | 0.02% | 101 |
|
|
2020
Q3 | $4.83M | Buy |
32,622
+6,730
| +26% | +$1.04M | 0.02% | 101 |
|
|
2020
Q2 | $4.25M | Sell |
25,892
-14,466
| -36% | -$2.22M | 0.02% | 106 |
|
|
2020
Q1 | $5.6M | Buy |
40,358
+386
| +1% | +$53K | 0.03% | 91 |
|
|
2019
Q4 | $5.25M | Buy |
39,972
+23,450
| +142% | +$2.72M | 0.03% | 106 |
|
|
2019
Q3 | $1.85M | Buy |
16,522
+45
| +0.3% | +$5.01K | 0.01% | 138 |
|
|
2019
Q2 | $1.83M | Sell |
16,477
-59,606
| -78% | -$7.02M | 0.01% | 137 |
|
|
2019
Q1 | $9.87M | Buy |
76,083
+60,686
| +394% | +$7.38M | 0.05% | 93 |
|
|
2018
Q4 | $1.78M | Buy |
15,397
+610
| +4% | +$68.1K | 0.01% | 129 |
|
|
2018
Q3 | $1.59M | Buy |
14,787
+500
| +3% | +$50K | 0.01% | 140 |
|
|
2018
Q2 | $1.22M | Sell |
14,287
-2,736
| -16% | -$225K | 0.01% | 149 |
|
|
2018
Q1 | $1.32M | Buy |
17,023
+650
| +4% | +$52.3K | 0.01% | 146 |
|
|
2017
Q4 | $1.38M | Sell |
16,373
-14
| -0.1% | -$1.19K | 0.01% | 142 |
|
|
2017
Q3 | $1.4M | Hold |
16,387
| – | – | 0.01% | 138 |
|
|
2017
Q2 | $1.35M | Sell |
16,387
-3,458
| -17% | -$282K | 0.01% | 144 |
|
|
2017
Q1 | $1.67M | Hold |
19,845
| – | – | 0.01% | 132 |
|
|
2016
Q4 | $1.46M | Sell |
19,845
-7,350
| -27% | -$547K | 0.01% | 143 |
|
|
2016
Q3 | $2.18M | Sell |
27,195
-2,490
| -8% | -$199K | 0.01% | 126 |
|
|
2016
Q2 | $2.34M | Buy |
29,685
+1,235
| +4% | +$93K | 0.01% | 126 |
|
|
2016
Q1 | $2.05M | Sell |
28,450
-5,074
| -15% | -$384K | 0.01% | 124 |
|
|
2015
Q4 | $2.82M | Buy |
33,524
+2,884
| +9% | +$239K | 0.02% | 117 |
|
|
2015
Q3 | $2.56M | Hold |
30,640
| – | – | 0.01% | 118 |
|
|
2015
Q2 | $2.56M | Sell |
30,640
-731
| -2% | -$55.7K | 0.01% | 114 |
|
|
2015
Q1 | $2.28M | Sell |
31,371
-150
| -0.5% | -$10.7K | 0.01% | 117 |
|
|
2014
Q4 | $2.17M | Sell |
31,521
-200
| -0.6% | -$13.5K | 0.01% | 118 |
|
|
2014
Q3 | $2.06M | Buy |
31,721
+150
| +0.5% | +$9.5K | 0.01% | 119 |
|
|
2014
Q2 | $1.96M | Buy |
31,571
+250
| +0.8% | +$14.9K | 0.01% | 124 |
|
|
2014
Q1 | $1.84M | Sell |
31,321
-341
| -1% | -$19K | 0.01% | 124 |
|
|
2013
Q4 | $1.61M | Buy |
+31,662
| New | +$1.59M | 0.01% | 128 |
|
|
2013
Q2 | $1.6M | Buy |
+32,587
| New | +$1.77M | 0.01% | 120 |
|
Other funds holding LLY
VCM
VPM
Fayez Sarofim & Co's LLY Position: Q1 2026 in Review
Fayez Sarofim & Co reduced its Eli Lilly (LLY) stake by 0.29% in Q1 2026, selling an estimated $1.24M and leaving 423,173 shares worth $389M. The position accounts for 1% of the portfolio, ranked #30.
Fayez Sarofim & Co first reported a position in LLY in Q2 2013 and has held it in 51 quarters since. The position peaked at $456M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Fayez Sarofim & Co held 423,173 shares of Eli Lilly worth $389M as of Q1 2026.
- Fayez Sarofim & Co sold 1,223 Eli Lilly shares in Q1 2026, an estimated $1.24M.
- Eli Lilly made up 1% of Fayez Sarofim & Co's portfolio in Q1 2026, its #30 holding.
- Fayez Sarofim & Co first reported a position in Eli Lilly in Q2 2013 and has held it in 51 quarters since.
- Fayez Sarofim & Co's Eli Lilly position peaked at $456M in Q4 2025.
- 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Fayez Sarofim & Co's 13F filing for Q1 2026, filed 15 May 2026.